Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
S Assoun, N Theou-Anton, M Nguenang, A Cazes… - Lung cancer, 2019 - Elsevier
Introduction Tumor mutational burden (TMB) correlates with response to immune checkpoint
inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that …
inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that …
[HTML][HTML] Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Background Paraneoplastic syndromes (PNS) are autoimmune disorders specifically
associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in …
associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in …
[HTML][HTML] Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study
Background The optimal treatment for patients with severe coronavirus-19 disease (COVID-
19) and hyper-inflammation remains debated. Material and methods A cohort study was …
19) and hyper-inflammation remains debated. Material and methods A cohort study was …
Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment
J Pluvy, S Brosseau, C Naltet… - European …, 2017 - Eur Respiratory Soc
Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major
leukocytosis following nivolumab treatment | European Respiratory Society Skip to main content …
leukocytosis following nivolumab treatment | European Respiratory Society Skip to main content …
Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and …
C Vauchier, J Pluvy, N Theou-Anton, G Soussi, N Poté… - Lung Cancer, 2021 - Elsevier
Immunotherapy with immune checkpoint inhibitors (ICIs) represents a major breakthrough in
lung cancer treatment. For patients with advanced non-small-cell lung cancer (NSCLC) and …
lung cancer treatment. For patients with advanced non-small-cell lung cancer (NSCLC) and …
Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis
B Duchemann, J Pluvy, B Crestani… - European Journal of …, 2021 - ejcancer.com
Antiprogrammed cell death-1 (PD-1) immunotherapies are a new standard of care for
patients with advanced non small cell lung cancer (NSCLC) in most situations. Despite a …
patients with advanced non small cell lung cancer (NSCLC) in most situations. Despite a …
Epidemiology of lung cancer in France and in the world
S Brosseau, J Pluvy, G Soussi, G Zalcman… - La Revue du …, 2020 - europepmc.org
Epidemiology of lung cancer in france and in the world. Lung cancer is the leading cause of
death from cancer worldwide. In France, lung cancer is the second most common cancer in …
death from cancer worldwide. In France, lung cancer is the second most common cancer in …
[HTML][HTML] Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor …
C Bouchez, J Pluvy, G Soussi, M Nguenang… - BMC cancer, 2020 - Springer
Background Choroidal metastases are the most common eye metastatic site. The
prevalence of choroidal metastases in NSCLC patients has been reported to vary from 0.2 to …
prevalence of choroidal metastases in NSCLC patients has been reported to vary from 0.2 to …
[HTML][HTML] Measuring walking speed failed to predict early death and toxicity in elderly patients with metastatic non-small-cell lung cancer (NSCLC) selected for …
A Aregui, J Pluvy, M Sanchez, T Israel, H Esnault… - Cancers, 2022 - mdpi.com
Simple Summary Lung cancer is common in elderly adults. Onco-geriatric tools are meant to
constitute a global approach designed to help oncologists to determine which elderly …
constitute a global approach designed to help oncologists to determine which elderly …
A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient
E Guenzi, J Pluvy, A Guyard, M Nguenang… - ERJ Open …, 2021 - Eur Respiratory Soc
In cancer patients, ERBB4 fusions have been reported in the literature with various gene
partners (IKZF, B4GALT5 and EZR)[1–3] allowing dimerisation and constitutive activation of …
partners (IKZF, B4GALT5 and EZR)[1–3] allowing dimerisation and constitutive activation of …